Skip to main content

'Alarming' Increase in Stroke Risk Factors

Despite many prevention initiatives, the prevalence of conventional stroke risk factors, including hypertension, diabetes, dyslipidemia, drug abuse, and smoking, actually appears to be on the rise among new ischemic stroke patients in the United States, a new study shows.
Other vascular conditions, such as chronic renal failure, coronary artery disease, and carotid stenosis, also appear to be increasing in the acute ischemic stroke population.
These observations come from a new analysis of data from the Nationwide Inpatient Sample, which includes 922,451 hospitalizations for acute ischemic stroke. The authors say this represents "the most comprehensive assessment to date of temporal trends in the prevalence of major stroke risk factors."
The study was published online in Neurology on October 11.
"Our data show that all risk factors increased from 2004 to 2014 and the prevalence of raised cholesterol more than doubled during this time. These are truly alarming findings," lead author, Fadar Oliver Otite, MD, University of Miami Miller School of Medicine, Florida,  told Medscape Medical News.
"While we are putting a great deal of effort into trying to control cardiovascular risk factors, this is not adequate. We need more coordinated strategies to try and tackle this problem," he added.
However, an accompanying editorial points out some limitations of the study and cautions against interpreting the data at face value. 
Results of the study show that across the 2004–2014 period, 92.5% of patients with acute ischemic stroke had one or more risk factors. Overall the age- and sex-adjusted prevalence of hypertension was 79%; diabetes, 34%; dyslipidemia, 47%; smoking, 15%; and drug abuse, 2%.  In addition, 13% of patients had carotid stenosis, 12% had chronic renal failure, and 27% had coronary artery disease.
The analysis suggested that during the study period the prevalence of hypertension increased annually by 1.4%, diabetes by 2%, dyslipidemia by 7%, smoking by 5%, and drug abuse by 7%. Prevalence of chronic renal failure increased annually by 13%, carotid stenosis by 6%, and coronary artery disease by 1%.
During the whole 10 years of the study, diabetes prevalence increased from 30.7% in 2004 to 37.5% in 2014 in all patients, with higher rates in Hispanics and blacks than in whites. By 2014, 50% of Hispanic participants with acute ischemic stroke had diabetes. Stroke admissions with both hypertension and diabetes increased from 25.1% in 2004 to 34.2% in 2014.
Overall dyslipidemia prevalence more than doubled during the study period — from 28.9% in 2004 to 58.6% in 2014. Admissions with concomitant hypertension, diabetes, and dyslipidemia increased by more than 200% from 9.4% in 2004 to 23.7% in 2014.
In terms of other vascular diseases, chronic renal failure saw the largest increase — from 4.8% in 2004 to 15.0% in 2014.
"These results indicate that modifiable stroke risk factors continue to pose significant challenges for AIS [acute ischemic stroke] prevention in the United States and call for intensification of proven treatment strategies and development of novel comprehensive preventive approaches," the researchers write.
Noting that many of the risk factors are higher in blacks and Hispanics, they suggest that "specific interventions targeting these underrepresented populations may potentially yield major gains for ischemic stroke prevention."
They further point out that fewer than half of patients with dyslipidemia are receiving treatment for this condition and only around 30% have control of their low-density lipoprotein cholesterol. And up to half of the 75 million patients with hypertension in the United States have uncontrolled blood pressure and about 20% of patients with diabetes have hemoglobin A1c levels more than 9.0 mg/dL.
"Focusing on risk factor control is critical for stroke prevention," they conclude. "Our alarming findings support the call for further concerted action from all stakeholders to more effectively implement evidence-based interventions to reduce stroke risk."
But in the accompanying editorial, Shyam Prabhakaran, MD, points out that these new data contrast with other those from studies from Norway and the United Kingdom that found reductions in most stroke risk factors between 1995 and 2011.
He suggests that the Nationwide Inpatient Sample has several limitations that make it a suboptimal dataset from which to make epidemiologic inferences, including nonstandardized definitions of risk factors across hospitals, potential for coding errors and misclassification of risk factors, and changing definitions of various conditions during the study period.
He also notes that the lack of data on risk factor management and control "provides little insight on whether risk factors are simply accumulating unbeknownst to patients and therefore untreated, or whether they are being screened for, diagnosed early, and treated appropriately.
"Thus, instead of a national crisis of increasing risk factors among stroke patients, these same data could imply improved screening and diagnosis of multiple stroke risk factors prior to or at the time of stroke occurrence."
In addition, Dr Prabhakaran makes the point that an increasing prevalence of risk factors may also be explained by the declining cardiovascular and stroke mortality  because more people with multiple risk factors survive longer.
"So, while there should indeed be a call to action to prevent stroke and its negative consequences on society, we should acknowledge important progress that has been made in stroke prevention, even if there is much more work to be done," he concludes.
"We should also continue to search for data that measure the health of our society, but remain cautious in interpreting them in a vacuum or without the appropriate context."
Dr Otite has disclosed no relevant financial relationships.
Neurology. Published online October 11, 2017. AbstractEditorial

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...